Mycophenolate mofetil combination therapy improves long‐term outcomes after liver transplantation in patients with and without hepatitis C

Russell H. Wiesner, Jolene S. Shorr, Bettina J. Steffen, Alice H. Chu, Robert D. Gordon, John R. Lake – 22 June 2005 – To evaluate the impact of mycophenolate mofetil (MMF) on long‐term outcomes of tacrolimus and corticosteroids, we analyzed data reported to the Scientific Registry of Transplant Recipients for 11,670 adult patients (3463 with hepatitis C [HCV]) who underwent primary, single‐organ, liver transplantation between 1995 and 2001.

Liver transplantation for chronic hepatitis B with lamivudine‐resistant YMDD mutant using add‐on adefovir dipivoxil plus lamivudine

Chung Mau Lo, Chi Leung Liu, George K. Lau, See Ching Chan, Irene O. Ng, Sheung Tat Fan – 22 June 2005 – Lamivudine treatment in patients with chronic hepatitis B virus (HBV) infection may improve clinical state and suppress viral replication before liver transplantation. Emergence of lamivudine‐resistant YMDD mutant is common. We report the results of liver transplantation in 16 patients with pretransplantation YMDD mutants after receiving lamivudine treatment for a median of 738 days (range, 400‐1799 days).

Ischemia‐reperfusion of rat liver modulates hepcidin in vivo expression

John A. Goss, Philip Seu, Feng Qin Gao, Samuel Wyllie – 22 June 2005 – The recently identified acute‐phase response antimicrobial peptide hepcidin has been postulated to maintain iron homeostasis by modulating iron absorption at both the intestinal and macrophage levels. Hepcidin has also been reported to be responsible for anemia associated with chronic inflammatory diseases, and in anemia in patients with hepatic adenomas.

Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation

David P. Breen, Anthony M. Marinaki, Monica Arenas, Peter C. Hayes – 22 June 2005 – Azathioprine (AZA) is a thiopurine prodrug commonly used in triple‐immunosuppressive therapy following liver transplantation. Approximately 1 in 10 patients suffers side effects in response to the drug, the most problematic being bone marrow toxicity. There is evidence that polymorphisms in the genes encoding thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPase) predict adverse drug reactions to AZA therapy.

Systematic review and validation of prognostic models in liver transplantation

Matthew Jacob, James D. Lewsey, Carlos Sharpin, Alexander Gimson, Mohammed Rela, Jan H.P. van der Meulen – 22 June 2005 – A model that can accurately predict post–liver transplant mortality would be useful for clinical decision making, would help to provide patients with prognostic information, and would facilitate fair comparisons of surgical performance between transplant units.

Liver transplantation for cardiac failure in patients with hereditary hemorrhagic telangiectasia

Thierry Thevenot, Claire Vanlemmens, Vincent Di Martino, Marie‐Claude Becker, Pierre‐Olivier Denue, Bernadette Kantelip, Solange Bresson‐Hadni, Bruno Heyd, Georges Mantion, Jean‐Philippe Miguet – 22 June 2005 – Liver involvement in hereditary hemorrhagic telangiectasia may lead to high‐output cardiac failure. Few data have been reported on orthotopic liver transplantation (OLT) for these patients. In this paper, we describe two patients treated by OLT as a salvage procedure for cardiac failure, and we review literature on this subject.

Subscribe to